---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-007094"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T16:33:19.894168+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# PAVmed regains Nasdaq compliance after equity actions; enters 1-year monitoring

## Summary
- Notified Feb 14, 2025 that it regained compliance with Nasdaq Listing Rule 5550(b)(1) ($2.5M equity).
- Regained compliance via exchange of $22.3M notes for Series C preferred, $2.653M new preferred issuance, and Lucid Diagnostics deconsolidation.
- Subject to one-year Mandatory Panel Monitor until Feb 14, 2026; new deficiency could trigger delisting.
- Company previously received hearing panel extension to Jan 31, 2025 after failing market value rule.

## SEC filing metadata
- accession: 0001493152-25-007094
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315225007094/0001493152-25-007094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315225007094/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-007094
- JSON: https://secwatch.observer/filing/0001493152-25-007094.json
- Plain text: https://secwatch.observer/filing/0001493152-25-007094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.